Literature DB >> 10485456

Activation of the PI3'K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors.

W Du1, A Liu, G C Prendergast.   

Abstract

Farnesyltransferase inhibitors (FTIs) usually cause growth inhibition, but in certain preclinical settings they have been shown to induce apoptosis, a clinically desirable response. In this study, we show that the proapoptotic effects of FTIs in Ras-transformed cells are masked by activation of phosphatidylinositol 3'-kinase (PI3'K) or AKT, which are controlled by cytokines and integrins. The results implied that FTIs disrupt a signal that is crucial for survival of malignant cells, but not normal cells, if the PI3'K-AKT pathway is inactivated. Our findings have implications for clinical applications of FTIs where apoptotic responses would be preferred.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10485456

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

Review 1.  Anticancer drug targets: growth factors and growth factor signaling.

Authors:  J B Gibbs
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

2.  Targeted therapies for killing tumor cells.

Authors:  A F Gazdar; J D Minna
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

3.  Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies.

Authors:  John Kauh; Chantal Chanel-Vos; Daniel Escuin; Michael P Fanucchi; R Donald Harvey; Nabil Saba; Dong M Shin; Anthony Gal; Lin Pan; Michael Kutner; Suresh S Ramalingam; Laura Bender; Adam Marcus; Paraskevi Giannakakou; Fadlo R Khuri
Journal:  Cancer       Date:  2011-03-01       Impact factor: 6.860

4.  RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors.

Authors:  A x Liu; W Du; J P Liu; T M Jessell; G C Prendergast
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

5.  A farnesylated G-protein suppresses Akt phosphorylation in INS 832/13 cells and normal rat islets: regulation by pertussis toxin and PGE₂.

Authors:  Chandrashekara N Kyathanahalli; Anjaneyulu Kowluru
Journal:  Biochem Pharmacol       Date:  2011-03-23       Impact factor: 5.858

6.  Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma.

Authors:  Sehrish Javaid; Antje Schaefer; Craig M Goodwin; Victoria V Nguyen; Frances L Massey; Mariaelena Pierobon; Da'Jhnae Gambrell-Sanders; Andrew M Waters; Kathryn N Lambert; J Nathaniel Diehl; G Aaron Hobbs; Kris C Wood; Emanuel F Petricoin; Channing J Der; Adrienne D Cox
Journal:  Mol Cancer Ther       Date:  2022-05-04       Impact factor: 6.009

7.  Dissecting the roles of DR4, DR5 and c-FLIP in the regulation of geranylgeranyltransferase I inhibition-mediated augmentation of TRAIL-induced apoptosis.

Authors:  Shuzhen Chen; Lei Fu; Shruti M Raja; Ping Yue; Fadlo R Khuri; Shi-Yong Sun
Journal:  Mol Cancer       Date:  2010-01-29       Impact factor: 27.401

8.  Hsp25 and Hsp70 in rodent tumors treated with doxorubicin and lovastatin.

Authors:  Daniel R Ciocca; Viviana R Rozados; F Darío Cuello Carrión; Silvia I Gervasoni; Pablo Matar; O Graciela Scharovsky
Journal:  Cell Stress Chaperones       Date:  2003       Impact factor: 3.667

Review 9.  New targets for therapy in breast cancer: farnesyltransferase inhibitors.

Authors:  Julia Head; Stephen R D Johnston
Journal:  Breast Cancer Res       Date:  2004-10-06       Impact factor: 6.466

Review 10.  The prince and the pauper. A tale of anticancer targeted agents.

Authors:  Alfonso Dueñas-González; Patricia García-López; Luis Alonso Herrera; Jose Luis Medina-Franco; Aurora González-Fierro; Myrna Candelaria
Journal:  Mol Cancer       Date:  2008-10-23       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.